Abstract
Background
Deferasirox is a recently approved once-daily oral iron chelator that has been shown to reduce liver iron concentrations and serum ferritin levels to a similar extent as infusional deferoxamine.
Objective
To determine the cost effectiveness of deferasirox versus deferoxamine in patients with ß-thalassaemia major from a US healthcare system perspective.
Methods
A Markov model was used to estimate the total additional lifetime costs and QALYs gained with deferasirox versus deferoxamine in patients with ß-thalassaemia major and chronic iron overload from blood transfusions. Patients were assumed to be 3 years of age at initiation of chelation therapy and to receive prescribed dosages of deferasirox and deferoxamine that have been shown to be similarly effective in such patients. Compliance with chelation therapy and probabilities of iron overload-related cardiac disease and death by degree of compliance were estimated using data from published studies. Costs ($US, year 2006 values) of deferoxamine administration and iron overload-related cardiac disease were based on analyses of health insurance claims of transfusion-dependent thalassaemia patients. Utilities were based on a study of patient preferences for oral versus infusional chelation therapy, as well as published literature. Probabilistic and deterministic sensitivity analyses were employed to examine the robustness of the results to key assumptions.
Results
Deferasirox resulted in a gain of 4.5 QALYs per patient at an additional expected lifetime cost of $US126 018 per patient; the cost per QALY gained was $US28 255. The cost effectiveness of deferasirox versus deferoxamine was sensitive to the estimated costs of deferoxamine administration and the quality-of-life benefit associated with oral versus infusional therapy. Cost effectiveness was also relatively sensitive to the equivalent daily dose of deferasirox, and the unit costs of deferasirox and deferoxamine, and was more favourable in younger patients.
Conclusion
Results of this analysis of the cost effectiveness of oral deferasirox versus infusional deferoxamine suggest that deferasirox is a cost effective iron chelator from a US healthcare perspective.
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996; 95: 26–36
Cohen A. Management of iron overload in the pediatric patient. Hematol Oncol Clin North Am 1987; 3: 521–544
Arboretti R, Tognoni G, Alberti D. Pharmacosurveillance and quality of care of thalassaemic patients. Eur J Clin Pharmacol 2001; 56: 915–922
Nick H-P, Acklin P, Lattmann R, et al. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem 2003; 10: 1065–1076
Cappellini MD, Cohen A, Piga A, et al. A phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with. Blood 2006; 107 (9): 3455–3462
Weinstein MC, Toy EL, Sandberg EA, et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 2001; 4 (5): 348–361
Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13 (4): 322–338
Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices. Modeling studies. Value Health 2003; 6 (1): 9–17
Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89 (10): 1187–1193
Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet 1989; 2 (8653): 27–30
Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006 May 1; 107 (Epub 2005 Dec 13): 3738–3744
Fischer R, Longo F, Nielsen P, et al. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol 2003; 121 (6): 938–948
Piga A, Gagliotti C, Fogliacco E, et al. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003; 88: 489–496
Boturao-Neto E, Marcopito LF, Zago MA. Urinary iron excretion induced by intravenous infusion of deferoxamine in beta-thalassemia homozygous patients. Braz J Med Biol Res 2002; 35 (11): 1319–1328
Maggio A, D’Amico G, Morabito A, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis 2002; 28: 196–208
Ward A, Caro JJ, Green TC, et al. An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use. BMC Clin Pharmacol 2002; 2: 3
Taher A, Sheikh-Taha M, Koussa S, et al. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients. Eur J Haematol 2001; 67 (1): 30–34
Richardson ME, Matthews RN, Alison JF, et al. Prevention of heart disease by subcutaneous desferrioxamine in patients with thalassaemia major. Aust N Z J Med 1993; 23: 656–661
Beratis S. Noncompliance with iron chelation therapy in patients with beta thalassaemia. J Psychosom Res 1989; 33: 739–745
Wolfe L, Olivieri N, Sallan D, et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 1985; 312 (25): 1600–1603
Murri R, Antinori A, Ammassari A, et al. AdICoNA Study Group. Physician estimates of adherence and the patient-physician relationship as a setting to improve adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2002 Dec 15; 31 Suppl. 3: S158–S162.
Kalbfleisch JD, Prentic RL. The statistical analysis of failure time data. New York: John Wiley & Sons, Inc., 1980
Kremastinos DT, Tsetsos GA, Tsiapras DP, et al. Heart failure in beta thalassemia: a 5-year follow-up study. Am J Med 2001; 111 (5): 349–354
Anderson RN. United States life tables, 1998. National Vital Statistics Reports 2001; 48 (18) [online]. Available from URL: http://www.cdc.gov [Accessed 2006 Jun 21]
Bureau of Labor Statistics. Consumer price index. Washington, DC: US Department of Labor, 2006 [online]. Available from URL: http://data.bls.gov/cgi-bin/surveymost [Accessed 2006 Mar 5]
Red Book Update December 2006. Montvale (NJ): Thomson Healthcare Inc., 2005
Delea TE, Sofrygin O, Baladi J-F, et al. Costs and consequences of inadequate compliance with deferoxamine therapy in patients with transfusion-dependent thalassemia: session type [abstract 3134]. Blood 2005; 106 (11 Pt 1): 877a
De Abreu Lourenco R, Osborne R, Dalton A, et al. An oral iron chelator and quality of life [abstract 5553]. Blood 2005, 106 (11 Part 2)
Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993; 13 (2): 89–102
Briggs AH. A bayesian approach to stochastic cost-effectiveness analysis. Health Econ 1999; 8: 257–261
Weinstein MC, Fineberg HV, Elstein AS, et al. Clinical decision analysis. Philadelphia: W.B. Saunders, 1980: 260
Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20 (3): 332–342
Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn’t it increase at the rate of inflation. Arch Intern Med 2003; 163: 1637–1641
Pearson HA, Cohen AR, Giardina PJ, et al. The changing profile of homozygous beta-thalassemia: demography, ethnicity, and age distribution of current North American patients and changes in two decades. Pediatrics 1996; 97 (3): 352–356
RegenceRx Pharmacy Benefits Management. Therapeutic class reviewSM deferasirox (exjade®) [Novartis]. March 2006 [online]. Available from URL: http://www.regencerx.com/learn/physicianRx/index.html [Accessed 2006 Nov 12]
DeSwarte-Wallace J, Groncy PK, Finkelstein JZ. Iron chelation with deferoxamine: comparing the results of a critical pathway to a national survey. J Pediatr Hematol Oncol 1999; 21 (2): 136–141
Payne KA, Desrosiers MP, Proskorovsky I, et al. Total annual costs of infused iron chelation therapy in the United states [abstract 3360]. Poster presented at the American Society of Hematology 2006 Annual Meeting; 2006 Dec 11; Orlando
Cunningham MJ, Macklin EA, Neufeld EJ, et al. Thalassemia Clinical Research Network: complications of beta-thalassemia major in North America. Blood 2004; 104 (1): 34–39
Johnson ES, Sullivan SD, Mozaffari E, et al. A utility assessment of oral and intravenous ganciclovir for the maintenance treatment of AIDS-related cytomegalovirus retinitis. Pharma-coeconomics 1996; 10 (6): 623–629
Cappellini MD, Bejaoui M, Agaoglu L, et al. Patient satisfaction with deferasirox (exjade. Blood 2005; 106 (11 Pt 1): 759a
Acknowledgements
Funding for this study was provided by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. TE Delea and O Sofrygin are employees of Policy Analysis Inc. (PAI), an independent contract research organisation, which has received research support and consulting fees from Novartis. TE Delea has also received speaker honorarium from Novartis. SK Thomas and J-F Baladi are employees of Novartis and own stock and/or stock options in Novartis. PD Phatak has received consulting fees from PAI and honoraria from Novartis, and has served on advisory boards for Novartis. TD Coates has received consulting fees, research funding and honoraria from Novartis, has participated on advisory boards for Novartis, and is a member of the University Childrens Medical Group Speakers Bureau.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Delea, T.E., Sofrygin, O., Thomas, S.K. et al. Cost Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox versus Infusional Deferoxamine in Transfusion-Dependent Thalassaemia Patients. Pharmacoeconomics 25, 329–342 (2007). https://doi.org/10.2165/00019053-200725040-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200725040-00005